Terapia orientata alla matrice in adolescenti vicini all’età adulta e adulti affetti da osteogenesi imperfetta – studio “MOI-A”

Title

Code

MOI-A

Type

Sperimentale con farmaco

Start Year

2025

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Description

Studio promosso da IRCCS istituto Ortopedico Rizzoli e Sheffield Children’s NHS Foundation Trust, UK.

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. MOI-A

Wednesday 26 March 2025, 11:45

PG0004397_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

Terapia orientata alla matrice in adolescenti vicini all’età adulta e adulti affetti da osteogenesi imperfetta – studio “MOI-A”

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in